The Worldwide Innovative Network(WIN)Consortium in personalized cancer medicine is proud to announce that AstraZeneca,DKFZ and EORTC have joined the Consortium.WIN is a unique global network of leading academics,industries,payors and patient advocacy organizations working to make cancer precision medicine a reality for patients worldwide."It was formed on the premise that WIN members can accomplish together what no single institution can do alone"said Vladimir Lazar founder and Chief Operating Officer.WIN's goal is to significantly improve survival and quality of life of cancer patients in the next three years.Today WIN counts 32 members in 5 continents.
"We are thrilled that AstraZeneca,DKFZ and EORTC have become members of WIN,"stated Dr.John Mendelsohn,Chairman."With their advanced portfolios,innovations,technical capabilities and talented scientists,the new members will significantly enhance WIN's ability to bring the latest advances in precision cancer medicine to patients".
Dr.Antoine Yver MD,Head of Oncology,AstraZeneca's global medicines development unit,said:"Cancer is a devastating disease which has many forms,and there is still much to do in the search for new,targeted therapies to help patients.AstraZeneca has a rich heritage in oncology research and development and we can achieve a lot by joining forces with others to progress the best science and accelerate development of the next generation of medicines.At AstraZeneca,our aim is to advance our work in the area of personalized healthcare,helping to understand and address the underlying mechanisms of disease to get the right medicines to the right patients.We are delighted to join the WIN consortium and its rich global network of academic,pharmaceutical,information and translational business science partners.In doing so,it will provide access to our oncology pipeline,innovative science and our expertise to identify opportunities for combination therapies with potential to improve the lives of cancer patients everywhere."
